The U.S. Medical – Products industry is facing significant uncertainty as the government reinstates tariffs on medical devices, imposing rates from 10% to 145% on imports, particularly from China. This tariff increase threatens to disrupt the MedTech economy, with manufacturers understating the burden of heightened input costs which they cannot easily pass onto fixed-price hospital contracts. While U.S. personal protective equipment (PPE) manufacturers may benefit from reduced competition, supply chain complexities may arise, potentially leading to equipment shortages and budget strains for hospitals.
Despite these challenges, U.S. hospitals are anticipated to see budget increases due to improving demand and lower interest rates, which could boost medical product sales. The industry has recorded a 6.3% rise over the last year, outperforming the broader medical sector, which declined by 10%. Analysts express concern regarding ongoing supply chain issues and reduced demand for COVID-19-related products impacting growth, with the Zacks Medical Products industry currently ranked #186, placing it in the bottom 25% of over 250 industries.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
